Jiangsu Lianhuan Pharmaceutical Co Ltd

Lianhuan Pharmaceutical released its 2026 interim report. Total operating revenue reached 1.571 billion yuan, an increase of 285 million yuan compared with the same period last year, marking five consecutive years of growth and a year-on-year rise of 22.21%. Net profit attributable to the parent company was 10.52 million yuan, an increase of 50.55 million yuan from the same period last year, turning losses into gains. Net cash flow from operating activities was negative 84.62 million yuan, an improvement of 73.19 million yuan compared with the same period last year. The company's latest asset-liability ratio was 60.56%, gross margin was 28.67%, return on equity was 0.83%, and diluted earnings per share was 0.04 yuan.

Lianhuan Pharmaceutical announced that the company recently received the drug registration certificate for Lactulose Oral Solution approved and issued by the National Medical Products Administration. The drug specifications are 200 ml:133.4 g and 15 ml:10 g, registered as a Category 4 chemical drug, and deemed to have passed the consistency evaluation. The announcement shows that the drug is indicated for the treatment and prevention of chronic or habitual constipation and hepatic encephalopathy.

This evening, nearly 100 companies listed on the Shanghai Stock Exchange released a flurry of positive signals, spanning share buybacks and stake increases, improving business performance, proposed selections in centralized drug procurement, and interim dividend returns. On the buyback and stake increase front, two new buyback plans were added by Bethel Automotive Safety Systems and Shandong Hi-Speed, with a combined proposed buyback cap of 400 million yuan. Soochow Securities disclosed a controlling shareholder's stake increase plan, with a proposed increase amount not exceeding 200 million yuan, while another 76 companies simultaneously disclosed progress updates on buybacks and stake increases. At the operational level, results of the 12th round of national centralized drug procurement were gradually announced, with multiple Shanghai-listed pharmaceutical companies including Harbin Pharmaceutical Group, Zhejiang Huahai Pharmaceutical, China Resources Double-Crane Pharmaceutical, North China Pharmaceutical, Jiangsu Lianhuan Pharmaceutical, Aurisco Pharmaceutical, and Jianfeng Group declaring that their products have been proposed for selection. In terms of investor returns, four companies—WuXi AppTec, Zhejiang Jiuzhou Pharmaceutical, Kingfa Sci. & Tech., and Jasan Group—unveiled interim dividend plans on the same day. Among them, WuXi AppTec plans to distribute a cash dividend of 5.1 yuan per 10 shares, with the total interim dividend expected to exceed 1.5 billion yuan. Additionally, the controlling shareholder of Lujiazui voluntarily committed not to transfer or reduce its holdings in any way within the next 12 months, coinciding with the unlocking of restricted shares from the company's private placement.

Lianhuan Pharmaceutical announced that it has received the Chemical Active Pharmaceutical Ingredient Marketing Application Approval Notice for argatroban API from the National Medical Products Administration. The packaging specifications include 1 kg per bag, 2 kg per bag, and 5 kg per bag. Argatroban is a direct thrombin inhibitor, and its injection is indicated for improving neurological symptoms and daily activities in the acute phase of ischemic cerebral infarction, as well as improving symptoms associated with chronic arterial occlusive disease.

Lianhuan Pharmaceutical's controlling subsidiary, Changle Pharmaceutical, has received the Drug Registration Certificate for Dapagliflozin and Metformin Hydrochloride Extended-Release Tablets (I/II/III) issued by the National Medical Products Administration. The drug was approved as a Category 4 chemical drug, deemed to have passed the consistency evaluation, with specifications including 10 mg/1000 mg, 2.5 mg/1000 mg, and 5 mg/1000 mg, for use in improving glycemic control in adult patients with type 2 diabetes. The company stated that this approval will further enrich its product line, but it is not expected to have a significant impact on near-term performance, and the production and sales of the product are subject to uncertainties due to industry policies and market changes.